VolitionRx Ltd (VNRX): Revenue Growth QoQ

VNRX (VolitionRx Ltd.) - company brandmark

VolitionRx Limited generates revenue from the sale of diagnostic systems for medicine and veterinary science that analyze nucleosomes. The quarterly revenue growth vector demonstrates sales dynamics, where 157.60 represents the current metric level. Development relies on the commercialization of Nu.Q epigenetic panels and a digital IT platform that optimizes the distribution of oncology tests, increasing the transparency of medical sales channels.

VolitionRx Limited (VNRX) - Revenue Growth QoQ from 07/04/2022 to 11/20/2026

VolitionRx Ltd - analytical breakdowns and key metrics (VNRX)

- stock price and consensus target price:
- stock exchange capitalization data:
- cash and cash flow statistics:
Fundamental company analysis:volition.com - VNRX
Mass-produced product of VolitionRx Ltd.

Investors use this indicator for the early detection of business stagnation, where decelerating revenue growth rates foreshadow a price correction. The metric measures the percentage deviation of the current quarter's revenue from the previous one, and the change in quarterly sales volume confirms that the scientific potential of the epigenetics experts at VolitionRx Limited (VNRX) is capable of offsetting staffing shortages when scaling tests in the US market.